- Home
- PYPD vs RDI Comparison
PYPD vs RDI Comparison
Compare PYPD & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- RDI
- Stock Information
- Founded
- PYPD 2008
- RDI 1937
- Country
- PYPD Israel
- RDI United States
- Employees
- PYPD N/A
- RDI N/A
- Industry
- PYPD Medical/Dental Instruments
- RDI Movies/Entertainment
- Sector
- PYPD Health Care
- RDI Consumer Discretionary
- Exchange
- PYPD Nasdaq
- RDI Nasdaq
- Market Cap
- PYPD 26.7M
- RDI 30.1M
- IPO Year
- PYPD 2020
- RDI N/A
- Fundamental
- Price
- PYPD $2.90
- RDI $1.37
- Analyst Decision
- PYPD Strong Buy
- RDI Hold
- Analyst Count
- PYPD 2
- RDI 1
- Target Price
- PYPD $10.50
- RDI $2.40
- AVG Volume (30 Days)
- PYPD 19.1K
- RDI 33.3K
- Earning Date
- PYPD 05-14-2025
- RDI 05-23-2025
- Dividend Yield
- PYPD N/A
- RDI N/A
- EPS Growth
- PYPD N/A
- RDI N/A
- EPS
- PYPD N/A
- RDI N/A
- Revenue
- PYPD N/A
- RDI $210,527,000.00
- Revenue This Year
- PYPD N/A
- RDI $9.74
- Revenue Next Year
- PYPD N/A
- RDI $6.39
- P/E Ratio
- PYPD N/A
- RDI N/A
- Revenue Growth
- PYPD N/A
- RDI N/A
- 52 Week Low
- PYPD $2.30
- RDI $1.17
- 52 Week High
- PYPD $4.75
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- PYPD 56.83
- RDI 55.03
- Support Level
- PYPD $2.71
- RDI $1.34
- Resistance Level
- PYPD $2.89
- RDI $1.30
- Average True Range (ATR)
- PYPD 0.19
- RDI 0.07
- MACD
- PYPD 0.02
- RDI 0.01
- Stochastic Oscillator
- PYPD 56.25
- RDI 60.87
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.